Immune checkpoint inhibitors represent the most promising cancer therapy available to date. These inhibitors harness the patient’s own immune system to fight cancer, with remarkable and durable success. However, a large proportion of treated patients do not respond to this type of therapy, and the potential for serious side effects exists. Still lacking are reliable clinical biomarkers to identify appropriate candidates for immune checkpoint inhibitor therapy.
OncoHost is developing and validating a proprietary set of tests to identify cancer patients who are most likely to benefit from immune checkpoint inhibitor therapy. Our two leading indications are non-small cell lung cancer (NSCLC) and malignant melanoma.
Our predictive tests will optimize therapy decisions, reduce unnecessary toxicities and maximize clinical benefit.
Biomarkers that stratify patients likely to respond to therapy are now included in the majority of oncology clinical trials. PROphetTM can be used to enrich patient populations in Phase II-III trials. Our classification algorithms are designed to identify the key biological processes and proteins that drive the host response and accordingly predict which patient has a higher likelihood of responding to treatments.
PROphetTM is being used to identify key protein factors that drive tumor-promoting biological processes in the treated patient. Agents that selectively inhibit these key factors represent candidate drugs to be used in combination with standard-of-care therapies. This unique drug development program will help to maximize clinical outcomes, for more patients.
Our proof-of-concept preclinical studies demonstrate the benefit of various combination treatment strategies for a range of indications and therapy types. We are launching a clinical trial for glioblastoma patients undergoing standard-of-care therapy.